Suven Life Sciences gained 1.66% to Rs 33.60 at 11:48 IST on BSE after the company said it has secured patent rights in Mexico and Korea for two of its new chemical entities for the treatment of disorders associated with neurodegenerative diseases.
The stock hit a high of Rs 34.50 and a low of Rs 32.05 so far during the day. The stock had a 52-week high of Rs 64.45 on
The company’s current equity is Rs 11.57 crore. Face value per share is Rs 1.
The current price of Rs 33.60 discounts its Q3 December 2007 annualized EPS of Rs 0.70, by a PE multiple of 48.
Suven Life Sciences net profit declined 47.5% to Rs 2.01 crore on 12% fall in net sales to Rs 27.46 crore in Q3 December 2007 over Q3 December 2006.
The patents are valid till 2023.
Suven Life Sciences’ principal activity is to design, manufacture and the supply of bulk active, drug intermediates and fine chemicals to the life science industry. The company mainly operates in the
No comments:
Post a Comment